Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation (original) (raw)

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Kabatas S, Civelek E, Savrunlu EC, Karaaslan U, Yıldız Ö, Karaöz E. Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation. World J Methodol 2025; 15(1): 95857 [DOI: 10.5662/wjm.v15.i1.95857]

Corresponding Author of This Article

Serdar Kabatas, MD, Full Professor, Department of Neurosurgery, University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital, Karayolları Mahallesi, Osmanbey Caddesi 616. Sokak No. 10, Gaziosmanpaşa, Istanbul 34255, Türkiye. kabatasserdar@hotmail.com

Research Domain of This Article

Cell & Tissue Engineering

Article-Type of This Article

Clinical Trials Study

Open-Access Policy of This Article

This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-1) series.

Publishing Process of This Article

The chart showing Browse series, Download series.

Mar 20, 2025 (publication date) through Nov 19, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

World J Methodol. Mar 20, 2025; 15(1): 95857
Published online Mar 20, 2025. doi: 10.5662/wjm.v15.i1.95857

Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation

Serdar Kabatas, Erdinç Civelek, Eyüp Can Savrunlu, Department of Neurosurgery, University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital, Istanbul 34255, Türkiye

Serdar Kabatas, Erdinç Civelek, Department of Pediatric Allergy-Immunology, Institute of Health Sciences Marmara University, Istanbul 34865, Türkiye

Serdar Kabatas, Center for Stem Cell & Gene Therapy Research and Practice, University of Health Sciences Turkey, Istanbul 34255, Türkiye

Umut Karaaslan, Department of Child and Adolescent Psychiatry, University of Health Sciences, Gaziosmanpaşa Training and Research Hospital, Istanbul 34255, Türkiye

Özlem Yıldız, Department of Child and Adolescent Psychiatry, Kocaeli University Faculty of Medicine, Kocaeli 41001, Türkiye

Erdal Karaöz, Center for Regenerative Medicine and Stem Cell Research & Manufacturing, Liv Hospital, Istanbul 34340, Türkiye

Erdal Karaöz, Department of Histology and Embryology, Istinye University, Faculty of Medicine, Istanbul 34010, Türkiye

Erdal Karaöz, Center for Stem Cell and Tissue Engineering Research and Practice, Istinye University, Istanbul 34340, Türkiye

Author contributions: Kabataş S and Civelek E contributed to the concept; Kabataş S, Civelek E, and Savrunlu EC, contributed to the design; Kabataş S and Karaöz E contributed to the supervision; Civelek E, Kabataş S, Savrunlu EC, Karaaslan U, and Yıldız Ö contributed to the analysis and/or interpretation; Kabataş S, Civelek E, and Savrunlu EC contributed to the literature search; Kabataş S, Civelek E, Savrunlu EC, Karaaslan U, Yıldız Ö, and Karaöz E contributed to the writing; Kabatas S, Civelek E, and Savrunlu EC contributed to the critical reviews.

Informed consent statement: There is human subject in this article and written informed consents were obtained from the patient for their anonymized information to be published in this article and before the stem cell therapies.

Clinical trial registration statement: Our research constitutes a pilot study rather than a randomized controlled trial. Consequently, it was not formally registered. Our intention is for this pilot study to pave the way for future randomized studies.

Conflict-of-interest statement: All authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Serdar Kabatas, MD, Full Professor, Department of Neurosurgery, University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital, Karayolları Mahallesi, Osmanbey Caddesi 616. Sokak No. 10, Gaziosmanpaşa, Istanbul 34255, Türkiye. kabatasserdar@hotmail.com

Received: April 20, 2024
Revised: June 23, 2024
Accepted: August 2, 2024
Published online: March 20, 2025
Processing time: 161 Days and 21.5 Hours

Abstract

BACKGROUND

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with multifaceted origins. In recent studies, neuroinflammation and immune dysregulation have come to the forefront in its pathogenesis. There are studies suggesting that stem cell therapy may be effective in the treatment of ASD.

AIM

To evolve the landscape of ASD treatment, focusing on the potential benefits and safety of stem cell transplantation.

METHODS

A detailed case report is presented, displaying the positive outcomes observed in a child who underwent intrathecal and intravenous Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) transplantation combined with neurorehabilitation.

RESULTS

The study demonstrates a significant improvement in the child’s functional outcomes (Childhood Autism Rating Scale, Denver 2 Developmental Screening Test), especially in language and gross motor skills. No serious side effects were encountered during the 2-year follow-up.

CONCLUSION

The findings support the safety and effectiveness of WJ-MSC transplantation in managing ASD.

Core Tip: According to data of the World Health Organization, autism spectrum disorder (ASD) is observed in approximately 1 in every 100 children. Recent studies have revealed that immune factors and inflammation are effective in the development of ASD. In this study, we applied six doses of Wharton’s jelly-derived mesenchymal stem cell therapy to a 4-year-old patient diagnosed with autism spectrum disorder. After the applications, we observed the patient for 2 years. We did not encounter any serious side effects. According to the Childhood Autism Rating Scale values and Denver II Developmental Screening Test values, we detected significant improvements.